Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis...
-
NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis...
-
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough ~ Statistically significant and clinically relevant improvements in patient reported outcomes in...
-
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough ~ Statistically significant and clinically relevant improvements in patient reported outcomes in...